New Drug Tested at UC Health Is a Game-Changer for People with MS

Share
Doctor sitting in his office

Aram Zabeti, MD, is the medical director of the UC Waddell Center for Multiple Sclerosis. Photo by Cindy Starr.

A new drug approved by the Food and Drug Administration and studied at the University of Cincinnati Gardner Neuroscience Institute will be a game-changer for hundreds of patients treated at the Waddell Center for Multiple Sclerosis. The Waddell Center was part of the pivotal phase 3 clinical trial that led to the drug’s approval.

Approved for both types of MS and the first ever approved for the most aggressive form, it is the only drug with the most important qualities of an MS medication, says Aram Zabeti, MD, the Waddell Center’s director. “It is relatively safe and effective, and it is convenient for the patient and provider. The drug also meets the three goals of treatment. It can effectively control relapse, significantly reduce the number of future MRI lesions, and slow down the disability progression.”

The new drug, whose generic name is ocrelizumab, will be marketed by Genentech/Roche as Ocrevus. It was approved for relapsing remitting MS, the most common type, and for primary progressive MS, a rapidly debilitating condition that leads to paralysis and affects approximately 10 to 15 percent of people with MS. There previously was no treatment for primary progressive MS.

“We have been able to offer ocrelizumab to our patients since 2012 through this clinical trial and have gained a lot of experience as a result,” Zabeti says. The center is also taking part in a second clinical trial of ocrelizumab for patients who have failed other MS treatments. That trial is open for enrollment.

Drug Provides Convenience and Lower Cost

Using a unique mechanism of action that is new to MS treatment, the drug targets a subgroup of immune cells (B cells) that are believed to play an important role in the disease process by mistakenly attacking the protective myelin sheath on the axon of neurons. The drug reduced the relapse rate and disability progression in people with the relapsing form of MS by nearly half compared to an existing MS medication, Rebif, and prevented MRI lesions. Patients with primary progressive MS had a lower rate of disability progression with Ocrevus compared to patients taking a placebo.

The “convenience” factor of Ocrevus is critical, Zabeti says, because some MS medications have burdensome delivery methods, adverse side effects and tedious monitoring requirements. “Some treatments have had so much burden for the physician and the patient that the patient stops taking the medication or doesn’t follow through with the required monitoring protocols,” Zabeti says.

Studies have shown that one-half of all patients taking injectable medications for MS will stop adhering to their treatment plan within a year.

“Ocrevus is delivered by infusion only twice a year, so it will impose a relatively small inconvenience on MS patients, most of whom are young and active,” Zabeti says. “Another advantage of infusion therapy is the ability of providers to monitor patient adherence.”

Like other MS treatments, Ocrevus does have side effects. These include infusion reaction, increased risk of infection, and malignancy. While there were no cases of opportunistic infection in clinical trials, and the rate of malignancy was comparable to what is seen in the general population, Zabeti cautions that rare side effects could be discovered once the medication enters the market and is used by a large patient population. Zabeti adds that a medication that works for one patient may not work for another, and that patients should always discuss their treatment goals and plans with their doctor.

Although Ocrevus will cost $65,000 a year, Zabeti says it will be among the least expensive drugs for MS. “I was shocked and happily surprised. The MS community has been very frustrated to see drug prices increasing every year, even for a medication that was discovered 20 years ago. I think the competitive price of Ocrevus could have an impact on what other pharmaceutical companies charge.”

Genentech, a division of Roche, reported that it purposefully set the price 25 percent below the current average price of an MS medication.

The Waddell Center cares for 3,000 patients with MS at its four locations: Cincinnati, Dayton and West Chester, Ohio, and Florence, Kentucky. The Waddell clinical team is led by four neurologists (including Zabeti) who have completed fellowship training in multiple sclerosis.

— Cindy Starr

This entry was posted in UC Gardner Neuroscience Blog and tagged , , , , , , , , , . Bookmark the permalink. Both comments and trackbacks are currently closed.
  • Print This Page
  • Make an Appointment: Schedule Now
  • Sign up for our newsletter!
  • UCNI Weekly Blog
  • Hope Stories

    • Richard’s Story: Ruptured Aneurysms

      Richard's Story: Ruptured Aneurysms Almost three years ago, Richard “Dick” Watson, MD, found himself in an unfamiliar position for a doctor: lying on the operating table instead of standing over it. He didn’t know it at the time, but it was the beginning of...
    • Alicia’s Story: Multiple Sclerosis

      Alicia’s Story: Multiple SclerosisAlicia is relishing a life that is filled to the brim: she is a wife, a mother, a runner and a master at living with multiple sclerosis. Diagnosed in the late 1990s, Alicia had “a bumpy ride” in the beginning. But...
    • Janis’s Story: Levodopa Pump for Parkinson’s Disease

      Janis's Story: Levodopa Pump for Parkinson's Disease When Janis Yelton gratefully enrolled in a ground-breaking study at the University of Cincinnati Gardner Neuroscience Institute, she was wracked by pain from advanced Parkinson’s disease, taking 32 pills a day, and no longer able to work. Years later, Janis still...
    • Zettie’s Story: Aphasia

      Zettie's Story: Aphasia In November of 2004, Zettie Williams confronted what neurologists consider one of the most feared consequences of stroke. When a therapist showed her a photograph of her son, she knew she was looking at her son, but she couldn’t say...
    • Scott’s Story: The Epilepsy Ambassador

      Scott's Story: The Epilepsy AmbassadorScott was working his dream job as a commercial airline pilot 10 years ago when his life was forever changed by epilepsy. After coming home from a long run, he complained of nausea and then collapsed with a grand mal...
    • Norma’s Story: Essential Tremor

      Norma's Story: Essential TremorQuestion: what progressive neurological condition causes a rhythmic trembling of the head, voice, legs or trunk; can be treated with medication or deep brain stimulation; has no definitive cure; and is eight times more common than Parkinson’s disease? If you’re...
    • Brian’s Story: Vocal Cord Cyst

      Brian's Story: Vocal Cord Cyst One by one, the symptoms of a throat problem tapped on the pastor’s door. Pastor Brian Tome, leader of Crossroads Church and speaker of five weekly messages to a following of 15,000, acknowledged the symptoms and tried to dismiss them....
    • Frank’s Story: Parkinson’s Disease

      Frank's Story: Parkinson's DiseaseSome people have vacation homes. Frank has the UC Gardner Neuroscience Institute. This is where he comes for comprehensive, compassionate medical care for Parkinson’s disease, which he has lived with for 15 years. “They make us feel safe,” says Frank’s wife,...
    • Troy’s Testimonial: ‘Out of 5 Stars, They Get 6’

      Troy’s Testimonial: ‘Out of 5 Stars, They Get 6’ Troy Sheldon has something to say, and he’d like...
    • Dick’s Story: Limbic Encephalitis

      Dick's Story: Limbic EncephalitisDick was enjoying his retirement as a full-time volunteer at Crayons to Computers when his memory began to go awry. He told his granddaughter that his car was due for an oil change, when he had just had the oil...